Lake Hills Wealth Management LLC Takes Position in Natera, Inc. (NASDAQ:NTRA)

Lake Hills Wealth Management LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,112 shares of the medical research company's stock, valued at approximately $440,000. Natera makes up about 0.3% of Lake Hills Wealth Management LLC's investment portfolio, making the stock its 27th largest holding.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after buying an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP lifted its position in Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after buying an additional 439,778 shares during the period. Finally, Geode Capital Management LLC lifted its position in Natera by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after buying an additional 142,201 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on NTRA shares. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. UBS Group increased their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Robert W. Baird lifted their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Down 1.1%

NASDAQ:NTRA traded down $1.75 during mid-day trading on Friday, hitting $163.76. The company had a trading volume of 1,016,903 shares, compared to its average volume of 1,409,610. The business has a fifty day simple moving average of $151.77 and a 200-day simple moving average of $158.53. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm has a market capitalization of $22.36 billion, a price-to-earnings ratio of -93.05 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's revenue was up 36.5% compared to the same quarter last year. During the same period last year, the company posted ($0.56) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 9,563 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the transaction, the chief executive officer now owns 212,541 shares in the company, valued at approximately $29,417,799.81. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 1,026 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the completion of the transaction, the insider now owns 144,782 shares in the company, valued at approximately $21,143,963.28. This trade represents a 0.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,275 shares of company stock worth $10,075,783 over the last 90 days. Company insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.